For the quarter ending 2025-06-30, YMAB made $19,525K in revenue. -$5,252K in net income. Net profit margin of -26.90%.
| Income Statement | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 19,525 | 20,904 | 17,904* | 18,461 |
| Cost of goods sold | 2,662 | 3,001 | 7,108* | 2,248 |
| Gross profit | 16,863 | 17,903 | 10,796* | - |
| Research and development | 11,104 | 11,359 | 6,021* | 11,168 |
| Selling, general, and administrative | 11,313 | 13,087 | 8,378* | 13,613 |
| License royalties | 50 | - | 63* | - |
| Total operating costs and expenses | 22,467 | 24,446 | 14,461* | 27,029 |
| Loss from operations | -5,604 | -6,543 | -3,665* | -8,568 |
| Interest and other income | 2,372 | 1,352 | -2,445* | 1,916 |
| Loss before income taxes | -3,232 | -5,191 | -6,110* | -6,652 |
| Provision for income taxes | 7 | 5 | -815* | 346 |
| Net loss | -3,239 | -5,196 | -5,295* | -6,998 |
| Foreign currency translation | -2,013 | -863 | 3,141* | -1,083 |
| Comprehensive loss | -5,252 | -6,059 | -2,154 | -8,081 |
| Basic EPS | -0.07 | -0.12 | -0.049 | -0.16 |
| Diluted EPS | -0.07 | -0.12 | -0.049 | -0.16 |
| Basic Average Shares | 45,318,000 | 45,104,476 | 44,337,587 | 44,626,943 |
| Diluted Average Shares | 45,318,000 | 45,104,476 | 44,337,587 | 44,626,943 |
Y-mAbs Therapeutics, Inc. (YMAB)
Y-mAbs Therapeutics, Inc. (YMAB)